<DOC>
	<DOCNO>NCT02649218</DOCNO>
	<brief_summary>A safety extension study evaluate long-term safety QGE031 240 mg s.c. give every 4 week 52 week Chronic Spontaneous Urticaria patient complete study CQGE031C2201</brief_summary>
	<brief_title>A Safety Extension Study Evaluate Long-term Safety QGE031 Chronic Spontaneous Urticaria ( CSU ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<criteria>Patients eligible inclusion study fulfill follow criterion : 1 . Written informed consent must obtain assessment perform . 2 . Patients complete treatment epoch study CQGE031C2201 complete least Visit 203 ( Week 32 followup epoch , ≥16 week last injection ) present active disease define UAS7 ≥12 . 3 . Patients must miss eDiary entry 7 day prior Visit 301 ( patient allow repeat criterion meet ) . 4 . Willing able complete daily symptom eDiary duration study adhere study visit schedule . Clearly define underlying etiology chronic urticaria chronic spontaneous urticaria Evidence parasitic infection Any skin disease chronic spontaneous urticaria chronic itch Contraindications hypersensitivity fexofenadine , loratadine , cetirizine , epinephrine History anaphylaxis History current diagnosis ECG abnormalities indicate significant risk safety patient participate study History hypersensitivity study drug component similar chemical class Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>QGE031</keyword>
	<keyword>chronic</keyword>
	<keyword>spontaneous</keyword>
	<keyword>Urticaria</keyword>
	<keyword>CSU</keyword>
	<keyword>adult</keyword>
	<keyword>Safety</keyword>
</DOC>